Literature DB >> 6402913

Effects of verapamil on coronary hemodynamic function and vasomobility relative to its mechanism of antianginal action.

C Y Chew, B G Brown, B N Singh, M M Wong, C Pierce, R Petersen.   

Abstract

The effect of intravenous verapamil on systemic and coronary hemodynamic function was studied at cardiac catheterization in 12 patients with coronary artery disease. Verapamil was administered as a 2-minute bolus (0.145 mg/kg) followed by an infusion (0.005 mg/kg/min). Cardiac output and coronary sinus blood flow were measured by thermodilution techniques. Caliber of the large coronary arteries and of diseased segments was determined from the coronary angiogram using a computer-assisted method. Verapamil reduced mean arterial pressure 14% (p less than 0.001), systemic vascular resistance 21% (p less than 0.01), and stroke work index 16% (p less than 0.001). Coronary vascular resistance decreased 24% (p less than 0.01) with a small increase in coronary sinus blood flow (+13%, difference not significant [NS]). Myocardial oxygen consumption determined in 5 patients showed no significant change with verapamil. Luminal area in 39 coronary lesions was measured in the "normal" portion of the diseased segment and at its maximal constriction, and an estimate of flow resistance in the stenosis was computed. Overall, 50% of "normal" and of diseased coronary segments dilated significantly with verapamil. Stenosis dilation resulted in an average 14% reduction (p less than 0.01) in estimated flow resistance. In 8 patients, the luminal changes (n = 27) induced by sublingual nitroglycerin were compared with those induced by verapamil. Nitroglycerin induced a significantly greater increase in coronary caliber in both normal and diseased segments; estimated stenosis flow resistance decreased 28% with nitroglycerin compared with 14% with verapamil (p less than 0.01). Thus, verapamil moderately dilates the systemic and coronary small vessel resistance bed without apparently increasing myocardial metabolic demand. Furthermore, verapamil mildly dilates large coronary conductance vessels in both "normal" and diseased segments, although significantly less than does nitroglycerin.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6402913     DOI: 10.1016/s0002-9149(83)80118-0

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  9 in total

Review 1.  How to standardize vasomotor tone in serial studies based on quantitation of coronary dimensions?

Authors:  S Jost; C W Nolte; M Sturm; J Hausleiter; D Hausmann
Journal:  Int J Card Imaging       Date:  1998-12

Review 2.  Newer concepts in the pathogenesis of myocardial ischaemia. Implications for the evaluation of antianginal therapy.

Authors:  B N Singh; K Nademanee; M A Josephson
Journal:  Drugs       Date:  1986-07       Impact factor: 9.546

3.  Endogenous endothelin maintains coronary artery tone by endothelin type A receptor stimulation in patients undergoing coronary arteriography.

Authors:  Z S Kyriakides; D T Kremastinos; E Bofilis; D Tousoulis; A Antoniadis; D J Webb
Journal:  Heart       Date:  2000-08       Impact factor: 5.994

Review 4.  Verapamil. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension.

Authors:  D McTavish; E M Sorkin
Journal:  Drugs       Date:  1989-07       Impact factor: 9.546

Review 5.  Verapamil: a review of its pharmacological properties and therapeutic use in coronary artery disease.

Authors:  R N Brogden; P Benfield
Journal:  Drugs       Date:  1996-05       Impact factor: 9.546

6.  Effects of intravenous verapamil on left ventricular systolic function and diastolic filling dynamics in patients with coronary artery disease: analysis of intramyocardial markers.

Authors:  I Amende; R Simon; A Seegers; W P Hood; H D Schmittenkoetter
Journal:  Int J Card Imaging       Date:  1988

Review 7.  Calcium channel antagonists. Part II: Use and comparative properties of the three prototypical calcium antagonists in ischemic heart disease, including recommendations based on an analysis of 41 trials.

Authors:  L H Opie
Journal:  Cardiovasc Drugs Ther       Date:  1988-01       Impact factor: 3.727

Review 8.  Calcium Channel Blockers in Acute Care: The Links and Missing Links Between Hemodynamic Effects and Outcome Evidence.

Authors:  Jin Wang; David L McDonagh; Lingzhong Meng
Journal:  Am J Cardiovasc Drugs       Date:  2021-01       Impact factor: 3.571

Review 9.  The haemodynamic effects of nifedipine, verapamil and diltiazem in patients with coronary artery disease. A review.

Authors:  A L Soward; G L Vanhaleweyk; P W Serruys
Journal:  Drugs       Date:  1986-07       Impact factor: 9.546

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.